Nanomaterials for Diagnosis and Treatment of Common Neurological Disorders

Smart nanomaterials have emerged as a promising approach for drug delivery and the management of neurological diseases. Neurodegenerative disorders pose significant challenges in terms of treatment due to the limited ability of drugs to cross the blood–brain barrier (BBB) and effectively reach the affected regions in the central nervous system (CNS). However, advancements in nanotechnology offer exciting opportunities to overcome these limitations by utilizing smart nanomaterials for targeted drug delivery. Neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and others, are characterized by the gradual deterioration of neuronal structure and function, leading to neuronal death. Despite extensive drug screening efforts, no particular treatment is available that can cure these diseases or effectively reduce their progression. Smart nanomaterials, which possess the ability to respond and adapt to external stimuli, have distinct advantages for neuro-drug delivery. These nanomaterials can be engineered to respond to specific triggers, such as changes in temperature, pH, or enzymatic activity, to release drugs at the desired site within the body. This targeted drug delivery approach enhances therapeutic efficacy, minimizes side effects, and reduces the required dosage, thereby improving patient outcomes. Furthermore, smart nanomaterials can be functionalized to cross the BBB, allowing for the delivery of therapeutic agents directly to the brain. This approach holds great promise for the treatment of neurodegenerative disorders, as it enables higher drug concentrations at the site of action, improving treatment outcomes. Despite these promising advantages, the clinical translation of smart nanomaterials for neuro-drug delivery also faces challenges and limitations. Ensuring the safety and biocompatibility of these materials is crucial, as they interact with the intricate and sensitive structures of the CNS. A thorough assessment of toxicity, long-term effects, and potential immunological reactions is essential to mitigate any adverse effects on neuronal function or overall health. The journey toward clinical translation of nanomedicines for brain drug delivery is complex and requires careful consideration of regulatory and ethical issues. Adequate in vitro and animal models that accurately represent human physiology are essential for reliable and predictive outcomes in clinical trials.